Aurobindo Pharma Limited announced that the Prequalification Unit Inspection Team (PQT-INS) of World Health organization (WHO) had conducted an inspection at the Unit IV, a Formulation manufacturing facility, of APL Healthcare Limited, a wholly owned subsidiary of the Company, situated at Menakuru Village, Naidupeta Mandal, Tirupati District, Andhra Pradesh, from September 11 to September 15, 2023. Based on the inspection findings and response to the same, the PQT-INS has decided to recommend to the Prequalification Assessment Team that the above facility be named as a manufacturing site in the dossier for Dolutegravir, Lamivudine, Tenofovir Disoproxil Fumarate Tablets (50/300/300 mg).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,131 INR | +2.53% | +4.07% | +4.36% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.36% | 7.95B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- AUROPHARMA Stock
- News Aurobindo Pharma
- APL Healthcare Limited Subsidiary of Aurobindo Pharma Limited Announces Unit Inspection Team of World Health Organization Conducts an Inspection at the Unit IV